TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Anti-Ischemic Drug Therapy and Percutaneous Transluminal Angioplasty After Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Recent myocardial infarction within last 3 months~* Documented silent myocardial ischemia (type I)~Exclusion Criteria:~* Symptomatic myocardial ischemia

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic Participants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who are diagnosed with schizophrenia (diagnosis criteria: Diagnostic and Statistical Manual of Mental Disorders, fourth edition \[DSM-IV\])~* Participants who need to change the antipsychotic drug to another one for the following reasons among the participants treated with an antipsychotic drug for more than two weeks before the screening-Lack of efficacy, lack of tolerance or lack of compliance~* Participants who are capable of and willing to fill out the questionnaire for themselves~* Childbearing potential women who consent to the use of the consistently permissible contraception (oral contraceptive, contraceptive injection, intrauterine device, double barrier method and contraceptive patch)~* Participants who are compliant with self-medication or can receive consistent help or support~Exclusion Criteria:~* Participants with the past history of neuroleptic malignant syndrome (NMS), or with allergy or hypersensitivity to risperidone or paliperidone~* Participants who have taken clozapine within one month before screening~* Participants who are suspicious of having clinically significant risk including suicide or aggressive behavior and are expected to unable to complete the study (based on the investigator's judgment)~* Participants with severe preexisting gastrointestinal narrowing (pathologic or iatrogenic) or participants who cannot swallow the drug whole (The study drug must not be chewed, divided, melted or grinded because it can impact the study drug release profile)~* Participants with a known or suspected history (for 6 months and longer) of substance dependence according to the DSM-IV criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Paliperidone (Type: EXPERIMENTAL): Paliperidone Extended-Release (ER) oral tablet will be administered once daily at a starting dose of 6 milligram (mg) for 24 weeks, wherein dose range will be 3 to 12 mg per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Ear Neurostimulation for Adolescents With Functional Abdominal Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adolescents with a major complaint of abdominal pain (minimum 3/10 in severity) with or without nausea (minimum 3/10 in severity) of unclear etiology, who are English-speaking and willing to participate and consent to the study and who have a parent willing to participate.~* Patients with symptoms of minimum three times per week for a duration of two months or greater~* Intact external ear that is free of infection or severe dermatological conditions.~* Stable vital signs for their respective age~Exclusion Criteria:~* Medically complex children or those who take a medication or suffer from an organic disease that can explain symptoms will be excluded from participation.~* Children or parents, who have developmental delay, will be excluded due to difficulties in accurately completing the questionnaires and assessing symptoms.~* History of seizures~* Currently implanted electrical device~* Orthostatic hypotension

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Neurostimulator (Type: EXPERIMENTAL): Auricular neurostimulator treatment x 5 days each week for 4 consecutive weeks
- Sham Neurostimulator (Type: SHAM_COMPARATOR): Inactive auricular neurostimulator treatment x 5 days each week for 4 consecutive weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics and Safety Study of BI 695502 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Healthy males.~2. Complete medical history, including physical examination, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory tests.~3. Aged 21 to 50 years.~4. Body mass index below or equal to 30.~5. Body weight 65 to 95 kg, inclusive.~Exclusion criteria:~1. Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance.~2. Any evidence of a clinically relevant concomitant disease, as judged by the investigator.~3. History of relevant orthostatic hypotension, fainting spells, or blackouts.~4. Chronic or relevant acute infections.~5. History of relevant allergy/hypersensitivity (including allergy to the study medications or its excipients).~6. Intake of prescribed or over-the-counter drugs within less than 6 half-lives of the respective drug prior to study drug administration or during the trial.~7. Participation in another trial with a study medication within two months prior to administration or during the trial (six half-lives).~8. Smoker (\> 10 cigarettes or \> 3 cigars or \> 3 pipes/day).~9. Inability to refrain from smoking during days of confinement at the study center.~10. Current alcohol abuse as judged by the investigator.~11. Current drug abuse, as judged by the investigator.

- Gender: MALE
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- BI 695502 (Type: EXPERIMENTAL): Subject to receive one intravenous (i.v.) infusion of BI 695502
- bevacizumab A (Type: ACTIVE_COMPARATOR): Subject to receive one i.v. infusion of bevacizumab
- bevacizumab B (Type: ACTIVE_COMPARATOR): Subject to receive one i.v. infusion of bevacizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* primary IgA nephropathy~* age 18-75 years~* proteinuria range from 0.75 to 3.5g/d even after three-month treatment by sufficient ACEi/ARB~* eGFR\>30ml/min/1.73m2~Exclusion Criteria:~* immune suppressive agent in recent one years~* crescent glomerulonephritis, might use immune suppressive agent~* chronic hepatic disease~* myocardial infarction~* malignant hypertension~* stroke~* malignant tumor~* retinopathy~* other contraindication of Hydroxychloroquine~* pregnancy and breastfeeding women~* life expectancy for less than 6 months~* in other clinical trials~* not suitable for the study judged by investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Hydroxychloroquine Sulfate (Type: ACTIVE_COMPARATOR): 200mg Bid (eGFR\>60 ml/min/1.73m2), 100mg Tid (eGFR45-59 ml/min/1.73m2), 100mg Bid (eGFR 30-44 ml/min/1.73m2) and supportive treatment
- Placebo (Type: PLACEBO_COMPARATOR): Placebo and supportive treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent prior to any study specific procedures~* Female or male aged ≥40 years~* Diagnosed with Type 2 Diabetes~* High Risk for Cardiovascular events~Exclusion Criteria:~* Diagnosis of Type 1 diabetes mellitus History of bladder cancer or history of radiation therapy to the lower abdomen or pelvis at any time~* Chronic cystitis and/or recurrent urinary tract infections~* Pregnant or breast-feeding patients

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin (Type: EXPERIMENTAL): Dapagliflozin + standard of care therapy for Type 2 Diabetes and for co-morbidities and cardiovascular risk factors
- Placebo (Type: PLACEBO_COMPARATOR): Placebo + standard of care therapy for Type 2 Diabetes and for co-morbidities and cardiovascular risk factors

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Ozanimod in Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Ulcerative colitis (UC) confirmed on endoscopy~* Moderately to severely active UC (Mayo score 6-12)~Exclusion Criteria:~* Current use of anti-TNF agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 73 Years
- Healthy Volunteers: f

Study Arms:
- Ozanimod 0.5 mg (Type: EXPERIMENTAL): Participants received 0.5 mg capsules of ozanimod hydrochloride daily during the induction period weeks 0-9 (an initial 8-day dose escalation regimen in the induction period that consisted of 4 days of ozanimod HCl 0.25 mg (equivalent to ozanimod 0.23 mg), followed by 3 days of ozanimod HCl 0.5 mg, (equivalent to ozanimod 0.46 mg) followed by the assigned treatment level for at least 8 weeks. Participants who completed the induction period and were responders at week 8, continued to receive the same dose of ozanimod during the maintenance period up to week 32. Participants who received ozanimod 0.5 mg capsules and completed the induction period and were non-responders at Week 8 and who completed the maintenance period or experienced a disease relapse, were given the option to enter the OLP and receive 1 mg ozaninod capsules daily up to 6 years. Participants who had not shown clinical improvement 8 weeks after initiation of the OLP were discontinued from the study.
- Ozanimod 1 mg (Type: EXPERIMENTAL): Participants received 1 mg capsules of ozanimod hydrochloride daily during the induction period weeks 0-9 (an initial 8-day dose escalation regimen in the induction period that consisted of 4 days of ozanimod HCl 0.25 mg (equivalent to ozanimod 0.23 mg), followed by 3 days of ozanimod HCl 0.5 mg, (equivalent to ozanimod 0.46 mg) followed by the assigned treatment level for at least 8 weeks. Participants who completed the induction period and were responders at week 8, continued to receive the same dose of ozanimod during the maintenance period up to week 32. Participants who received ozanimod 1 mg capsules and completed the induction period and were non-responders at Week 8 and who completed the maintenance period or experienced a disease relapse, were given the option to enter the OLP and receive 1 mg ozaninod capsules daily up to 6 years. Participants who had not shown clinical improvement 8 weeks after initiation of the OLP were discontinued from the study.
- Placebo (Type: PLACEBO_COMPARATOR): Identically matching placebo capsules daily for 32 weeks followed by an optional open label treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 years of age~* Known HIV infection with stable HIV therapy for ≥ 6 months~* Cluster of differentiation 4 (CD4) ≥ 250 cells/mm\^3 for ≥ 6 months~* HIV viral load ≤ 50 copies/mL at screening and ≤ 200 copies/mL for ≥ 6 months~* Subject on stable lipid-lowering therapy for ≥ 4 weeks prior to randomization and not expected to change during the duration of study~* For subjects with known clinical atherosclerotic cardiovascular disease (ASCVD), fasting LDL-C of ≥ 70 mg/dL or non-high density lipoprotein cholesterol (non-HDL-C) ≥ 100 mg/dL. For subjects without known clinical ASCVD: fasting LDL-C of ≥ 100 mg/dL or non-HDL-C of ≥ 130 mg/dL~* Fasting triglycerides ≤ 600 mg/dL (6.8 mmol/L)~Exclusion Criteria:~* Taking a combination of background lipid-lowering therapy and HIV therapy known to have significant drug-drug interaction~* New York Heart Association (NYHA) III or IV heart failure, or last known left ventricular ejection fraction (LVEF) \< 30%~* Known opportunistic infection/acquired immunodeficiency syndrome (AIDS) defining illness within 1 year prior to randomization~* Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass graft or stroke within 3 months~* Type 1 diabetes, new-onset or poorly controlled type 2 diabetes~* Uncontrolled hypertension~* Taken a cholesteryl ester transfer protein inhibitor in the last 12 months~* Moderate to severe renal dysfunction~* Persistent active liver disease or hepatic dysfunction (Stable chronic hepatitis C of at least 1 year duration prior to randomization is allowed)~* Malignancy (except non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in-situ, or stage 1 prostate carcinoma) within the last 5 years prior to randomization~Other exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Double-Blind Placebo SC QM/Open-Label Evolocumab 420 mg SC QM (Type: EXPERIMENTAL): Double-blind placebo subcutaneous (SC) injection every 4 weeks (QM) for 24 weeks, followed by open-label evolocumab 420 mg SC QM for 24 weeks.
- Double-Blind Evolocumab 420 mg SC QM/Open-Label Evolocumab 420 mg SC QM (Type: PLACEBO_COMPARATOR): Double-blind evolocumab SC injection QM for 24 weeks, followed by open-label evolocumab 420 mg SC QM for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (18 or older)~* LDLT candidate~* HCV RNA positive~* Expected time on treatment is at least 12 weeks~* Candidates for DDLT who are listed for transplantation and meet UNOS criteria for MELD upgrade for HCC~Exclusion Criteria:~* Severe cytopenia (polymorphonuclear (PMN) leukocytes \< 750, OR hemoglobin \[Hgb\] \< 10 g/dL, OR platelet count \< 35,000/mm3)~* Uncontrolled depression or psychiatric disease characterized by current symptoms of major depression or other psychiatric disease or increase in medication for major depression or other psychiatric disease within the past three months.~* Uncontrolled cardiopulmonary disease characterized by myocardial infarction, coronary artery bypass graft surgery, Percutaneous coronary intervention, or unstable angina within the past three months.~* Uncontrolled autoimmune disease characterized by current symptoms of autoimmune disease or increase in medications within the last three months.~* Autoimmune hepatitis~* Active substance abuse within 6 months of initiation of treatment~* Known intolerance or serious adverse event during prior therapy with interferon or ribavirin~* Prior nonresponse after at least 24 weeks of full dose treatment with peginterferon plus ribavirin~* Laboratory Model for End-Stage Liver Disease (MELD) score \>20. Patients with laboratory MELD score 21-25 may be enrolled if deemed appropriate by the site investigator~* Serum creatinine \>2.2 mg/dL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LADR Treatment, Genotypes 1,4,6 (Type: EXPERIMENTAL): Subjects randomized to low accelerating dose regimen (LADR) treatment
- Standard care (Type: NO_INTERVENTION): Subjects randomized to Standard Care group, Genotypes 1,4,6
- LADR treatment, Genotypes 2,3 (Type: EXPERIMENTAL): Subjects randomized to low accelerating dose regimen (LADR) treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Willing to follow all the requirements of the study and available for follow-up for the duration of the study~* Have understanding of the study and provide written informed consent~* Willing to undergo HIV testing and counseling and willing to receive HIV test results~* Willing to use acceptable forms of contraception~Exclusion Criteria:~* HIV infected~* Hepatitis B virus infected~* Hepatitis C virus infected~* Active or untreated syphilis~* Participated in high-risk behavior for HIV infection within 6 months prior to study entry. More information on this criterion can be found in the protocol.~* Any clinically significant abnormality in history or upon examination (e.g., immunodeficiency or autoimmune disease; use of systemic corticosteroids, immunosuppressive, antiviral, anticancer, or other medications considered significant by the investigator) within 6 months prior to study entry~* Any clinically significant acute or chronic medical condition that, in the opinion of the investigator, would make the volunteer unsuitable for the study~* Live attenuated vaccines within 30 days prior to study entry OR plan to receive a live attenuated vaccine within 60 days after vaccination in this study~* Subunit or killed vaccines within 14 days prior to study entry OR plan to receive a subunit or killed vaccine within 14 days after vaccination in this study~* Blood transfusion or blood products within 120 days prior to study entry~* Immunoglobulin within 60 days prior to study entry~* Participation in another investigational product clinical trial in the 3 months prior to study entry OR expected to participate in another investigational trial during this study~* Any other investigational HIV vaccine at any time~* History of severe local or systemic reactogenicity to vaccines or history of severe allergic reactions~* Major psychiatric illness, including any history of schizophrenia or severe psychosis, bipolar disorder requiring therapy, or suicide attempt or suicidal thoughts within the 3 years prior to study entry~* Uncontrolled hypertension~* Pregnant, breastfeeding, or plan to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of LLF580 in Obese Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) within the range of 30 to 45 kg/m2, inclusive, with ethnic adjustment (≥27.5 kg/m2 for Asian individuals).~* Fasting triglyceride 150 - 500 mg/dL (1.69 - 5.65 mmol/L), inclusive, at screening.~* Able to communicate well with the investigator, to understand and comply with the requirements of the study.~Exclusion Criteria:~* History of hepatobilliary disease.~* Liver disease or liver injury as indicated by abnormal liver function tests.~* Chronic infection with Human Immunodeficiency Virus (HIV), Hepatitis B (HBV) or Hepatitis C (HCV).~* Fasting triglycerides greater than or equal to 500 mg/dL \[5.65 mmol/L\], or concomitant use of drug treatment for hypertriglyceridemia (fibrates, omega-3 fatty acids, nicotinic acid).~* History of pancreatic injury or pancreatitis.~* History of hypersensitivity to drugs of similar biological class, FGF21 protein analogue, or Fc fusion proteins.~* History of bone disorders or low vitamin D level.~* Contraindications to MRI.~* Change in body weight (more than 5% self-reported OR 5 kg self-reported change during the previous 3 months).~* Use of weight loss drugs.~* Enrollment in a diet, weight loss or exercise programs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- LLF580 (Type: EXPERIMENTAL): LLF580 every 28 days \* 3
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to LLF580 every 28 days \* 3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete